CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a minimally-invasive prognostic marker for predicting resistance to platinum-based chemotherapy in high-grade serous ovarian cancer. By analyzing isotopic variations in specific elements, the research aims to enhance early diagnosis and treatment strategies for this deadly cancer type…
Cancer is the second leading cause of death globally and in the EU, and was responsible for an estimated one in six deaths in 2018.
Early diagnosis plays an important role in determining cancer treatment outcomes, but the diagnosis of ovarian cancer poses significant challenges; the routine screening of asymptomatic average-risk women is not recommended by any professional society.
Chemotherapy using Pt-based compounds (e.g. carboplatin, cisplatin) is a standard treatment, but tumours that are i…
UNIVERSITEIT GENT
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
